Graham A. Colditz was awarded the 2021 American Association for Cancer Research Distinguished Lectureship on the Science of Cancer Health Disparities.
Virginia Commonwealth University Massey Cancer Center, Medical University of South Carolina Hollings Cancer Center, and City of Hope Comprehensive Cancer Center were awarded a SPORE grant from NCI that aims to address lung cancer racial disparities through precision medicine, targeted smoking cessation programs, and community outreach.
The American Cancer Society, along with four historically black medical schools including Charles Drew Medical School, Howard University, Meharry Medical College, and Morehouse School of Medicine, launched the Diversity in Cancer Research Program, which aims to improve diversity, equity, and inclusion in cancer research.
Huda Salman was named the first executive director of the Indiana University School of Medicine’s Brown Center for Immunotherapy, effective Nov. 1.
Velda González-Mercado, assistant professor at NYU Meyers, has received a grant from the National Institute of Nursing Research, supporting her research on the biologic underpinnings of cancer-related fatigue in men undergoing radiation therapy for prostate cancer, through a translational, bedside-to-bench omics approach.
Memorial Sloan Kettering Cancer Center has established the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers, which will unite experts across pediatric and adult specialties to improve cancer treatment for MSK patients aged 15 to 39.
The phase III GEMSTONE-301 study demonstrated the efficacy and safety of the anti-PD-L1 antibody sugemalimab as consolidation therapy in patients with locally advanced/unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
John Byrd has received the Binet-Rai Medal Award for his research findings, which led to the use of Bruton tyrosine kinase inhibitors in almost every phase of chronic lymphocytic leukemia therapy.
Results from a phase III trial demonstrated the clinical benefit of using PD-1 inhibitor Libtayo (cemiplimab), in combination with a physician’s choice of platinum-doublet chemotherapy, in the treatment of patients with locally advanced or metastatic non-small cell lung cancer, irrespective of histology and across all PD-L1 expression levels.
UCLA Jonsson Comprehensive Cancer Center researchers found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly mitigates disease progression, compared to the current standard of care, trastuzumab emtansine (T-DM1).
